INTRODUCTION
Many studies have shown that the final step in the cobalamin-dependent pathway of methionine synthesis in bacteria and in animal cells is catalyzed by N5-methyltetrahydrofolate-homocysteine methyltransferase (meth-chronic lymphocytic leukemia; CML, chronic myelocytic leukemia; FH4, tetrahydrofolate; methyltransferase, N5-methyltetrahydrofolate-homocysteine methyltransferase; M- Analogous enzymes have been characterized in Escherichia coli (2) (3) (4) and in various cells of animal origin (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Some evidence suggests that a major function of the enzyme is the maintenance of methionine levels in tissues. According to other evidence, the pathway has an essential role in producing FH4, which can enter into essential transfers of "one-carbon" units in various other pathways, e.g., the folate-dependent synthesis of thymidylate (16) . Doubtless, both views are correct, the relative importance of the two functions differing perhaps under different conditions.
Despite extensive discussion of an hypothesis that gives this pathway critical importance in the impairment of DNA synthesis associated with the megaloblastosis of vitamin Bi2 deficiency (reviewed in reference 17) , little is known of the distribution and characteristics of methyltransferase in human blood cells. This lack has motivated the present investigation. Human leukocytes were chosen for study since they include cells that are grossly altered morphologically by vitamin B12 deficiency (granulocytes) and cells that are not (lymphocytes); certainly though, evidence is available to suggest that vitamin B12 deficiency has effects on the immunologic function (18, 19) and chromosomal patterns (20, 21) of lymphocytes.
In the present study, methyltransferase activity was assayed in crude extracts of isolated granulocytes and lymphocytes, and kinetic properties of the enzymes in these extracts were characterized. The data show that lymphocytes contain higher enzyme levels than granulocytes, that lymphocytes from subjects with chronic lym-ML, myelomonocytic leukemia; PBS, potassium phosphate buffer, 10 mM, pH 7.4, in 0.9% NaCl; PV, polycythemia vera; SAM, S-adenosylmethionine.
The Journal of Clinical Investigation Volume 56 November 1975 56 November -1293 56 November -1301 phocytic leukemia (CLL) had even higher enzyme levels than normal lymphocytes, and that granulocytes contain one or more factors that inhibit methyltransferase activity.
METHODS
Reagents. Chemicals were obtained from the following sources: L-homocysteine thiolactone hydrochloride, S-adenosylmethionine chloride, folic acid, soybean and beef pancreas trypsin inhibitors, and bovine pancreas trypsin from Sigma Chemical Co., St. Louis, Mo., casein (Hammarsten quality) from Nutritional Biochemicals Corp., Cleveland, Ohio; cyanocobalaminandhydroxycobalamin from SchwarzMann Div., Becton, Dickinson & Co., Orangeburg, N. Y.; deoxyadenosylcobalamin from Calbiochem, San Diego, Calif. Samples of methylcobalamin were kindly provided by Dr. Bernard M. Babior, New England Medical Center, Boston, and Dr. Robert H. Abeles, Brandeis University, Waltham. Propylcobalamin was synthesized by reduction of cyanocobalamin with sodium borohydride, followed by alkylation with propyl bromide. The product was isolated by thinlayer chromatography on silica gel, using propanol: water: ammonium hydroxide (100: 99: 1) as solvent system (22) .
Nonradioactive d,l-CH3FH,, synthesized according to Blair and Saunders (23) , was purified by DEAE-cellulose chromatography according to Gupta and Huennekens (24) . N5-[1"C CH3-FH4 was purchased from Amersham/Searle Corp., Arlington Heights, Ill. Both products were chromatographically homogeneous and stable when stored under N2 at -20'C for 1 yr.
L-Homocysteine thiolactone hydrochloride was converted to L-homocysteine by exposure to 0.3 M NaOH (7-10 min), followed by neutralization with 0.3 M KH2PO4 (25) .
Preparation of lymphocytes and granulocytes. Venous blood (20-100 ml) was drawn from ostensibly normal donors (hospital personnel and patients without blood dyscrasias other than mild leukocytosis) and patients with CLL and other hematologic disorders that were untreated except as noted. Cell morphology in CLL patients studied was primarily that of typical small lymphocytes, without nucleoli, nuclear clefting, or pleomorphism. Normal subjects and CLL patients were not matched for age, the mean ages of the two groups being 26±4 and 63±+13 yr. Serum prepared from an aliquot of blood was stored at -100C for assay of serum folate and vitamin B12 levels by methods employing Lactobacillus casei (26) and Lactobacillus leichinannii (27) . Normal ranges in this laboratory for serum folate are 6-16 ng/ml and for serum vitamin B12 are 150-450 pg/ml. Heparin (Liquaemin sodium, The Upjohn Company, Kalamazoo, Mich.) was used as anticoagulant for blood samples (10-20 U/ml).
Leukocytes from normal subjects were obtained by mixing blood with 0.1 vol of 6%o dextran and sedimenting erythrocytes for 1 h at 370C (28) . The supernatant fraction was centrifuged at 100 g to remove platelet-rich plasma and leukocytes were suspended in 0.9%o NaCl. Lymphocytes and granulocytes were then separated in a Hypaque-Ficoll gradient according to Boyum (29) with centrifugation steps as modified by Handin et al. (30) . Collected lymphocytes were washed three times with icecold potassium phosphate buffer (PBS). Granulocytes collected from the pellet of the gradients, after lysis of erythrocytes (with 6 ml H20 for 30 s followed by 2 ml of 3.5%o NaCl), were washed twice with PBS. Cell counts and stained smears were prepared from the final suspension. About one to two contaminating platelets and a rare erythrocyte were observed per leukocyte. Final lymphocyte suspensions contained 0-2% granulocytes in CLL blood and 8-12% (3), with minor modifications (7). The standard assay system contained in a total volume of 0.5 ml: N-[14C]-CH3-FH4, 250 ,M (sp act, 400 cpm/nmol); SAM, 100 ,uM; L-homocysteine freshly prepared from the tliiolactone hydrochloride, 1.25 mM; cyanocobalamin, 100 jiM; ,B-mercaptoethanol, 200 mM; PBS, 50 mM, pH 7.4; and 0.5-1.0 mg of leukocyte protein or 0.2-0.3 mg of E. coli protein.
All incubations were carried out in duplicate. As noted below, parallel assays were ordinarily performed with and without added cyanocobalamin in the incubation mixture. Incubations lacking enzyme were used as blanks.
Standard-type incubations were conducted at 37°C for 1 h in the dark in air. Certain incubations, as indicated below, were conducted in an atmosphere of N2. All reactions were terminated by chilling on ice and addition of 1 ml of ice water. Aliquots of incubation mixtures were passed through 0. per hour. In most cases specific activities below 0.1 could not be reliably detected by the assay methods used. Specific activity of various E. coli extracts was 108-140. Reaction products of methyltransferase activity in leukocyte and E. coli extracts were identified as methionine by chromatography on Dowex 50-H' columns and then on Whatman no. 1 paper (butanol: acetic acid: water, 60:15: 25) (3, 32) . Radioassay of paper chromatogram showed that 88-97% of the radioactivity in reaction products was in the methionine and methionine sulfoxide regions. The amount of methionine formed increased as a linear function of time with incubation times up to 2 h in lymphocytes and E. coli extracts and as a linear function of enzyme concentration (1-5 mg protein for lymphocyte extracts, 0.3-1.0 mg for E. coli extracts). Km values were calculated by the Lineweaver-Burk method (33) .
Protease activity was measured as described by Laskowski with casein as substrate (34) . Protein was determined by a modification of the microbiuret method (35) . Routine hematological data were obtained by standard methods. RESULTS
Methyltransferase activity in leukocytes. Striking differences were observed in the methyltransferase activity of different classes of leukocytes (Tables I and   II) . Specific activity in lymphocytes from normal subjects in the standard assay system was 0.91±0tO.39 (Table II) . Lymphocytes from patients with CLL had a higher mean specific activity, the difference from normal lymphocytes being statistically significant (P = <0.001). Repeated determinations of enzyme activity on different blood samples from normal subjects and leukemic patients showed variations of less than 10% of the mean. Mixtures of normal lymphocyte and CLL extracts gave results predictable from the sums of their separate activities.
Cells from a child with acute lymphocytic leukemia (ALL) (patient 19) showed activity intermediate between that of normal and CLL lymphocytes. Similar values were found in lymphocytes of a patient with Sezary syndrome.
Omission of exogenous cyanocobalamin decreased the activity of methyltransferase in normal and CLL lymphocytes by about 65%. Even in the absence of added cyanocobalamin, the difference between normal and CLL cells was significant (P = < 0.01). Only traces To investigate the possibility that inhibition was due to the presence of cobalamin-binding proteins in the granulocyte extract (38, 39) increasing amounts of cyanocobalamin were added to standard incubation mixtures. The percent of inhibition of the E. coli methyltransferase reaction by normal granulocyte extract (0.6 mg of protein) was constant at cyanocobalamin concentrations up to 1.0 mM. E. coli enzyme was inhibited by cyanocobalamin concentrations above 1.0 mM without addition of granulocyte extract.
The inhibitor was not dialyzable. Its activity was decreased by 85 and 97% after heating to 60'C for 5 and 15 min, respectively. When soybean trypsin inhibitor was incubated in increasing amounts with a mixture of E. coli protein and CML extract, the inhibitory activity of CML cell extract was progressively lost (Table IV) . However, increased endogenous methyltransferase activity in CML cells was not detectable Table I ) and soybean trypsin inhibitor were added together in the shown amounts to incubations containing E. coli extract (0.25 mg protein) plus the standard incubation mixture. Patient was receiving busulfan. In a separate control experiment, soybean trypsin inhibitor in the absence of CML extract was shown to have no inhibitory effect on E. coli methyltransferase activity.
after incubation with soybean trypsin inhibitor. Pancreas trypsin inhibitor had no effect on CML cell inhibitor. CML extracts themselves lacked demonstrable proteolytic activity with casein as substrate. It is of interest that modest inhibition of CLL methyltransferase by CML extract was noted at low levels of CML protein (0.2 mg). However, activities returned to control levels with further additions of CML extract.
Cell extracts in amounts up to 0.5 mg protein from a patient with MML (patient 25, Table I) was only slightly inhibitory when tested against E. coli enzyme. Surprisingly, extracts from a patient with CLL not only failed to inhibit E. coli enzyme, but there was a regularly observed stimulation rising in an apparently hyperbolic manner with increasing additions of CLL extracts. In the experiment shown in Fig. 2 , the apparent rise in E. coli methyltransferase activity after addition of CLL extract reached a maximum of nearly 60%. The possible significance of this result will be the subject of a subsequent report.
DISCUSSION
The present results confirm the presence of methyltransferase in human leukocytes (12) and show that the enzyme is apparently cobalamin-dependent in lymphoid and myeloid cells. Its other cofactor requirements are also similar to those of methyltransferases from E. coli (3, 4, 37, 40) and various animal cell preparations (3, 5, 7, 11, 41, 42) . Enzyme activity is higher in normal lymphocytes than in granulocytes and is higher still in lymphocytes from patients with CLL. Others (12, 43) have found that leukocytic enzyme activity is increased in acute but not chronic leukemias. Since in these experiments lymphocytes were not isolated before preparation of cell extracts, reported normal values cannot be compared directly with the values reported here.
The data raise several points of interest. One concerns the enzymologic properties of leukocyte methyltransferase. Although studied only in unpurified extracts, the enzyme can be readily measured with precision. Activity is substantially stimulated by an added cobalamin derivative, but significant activity remains in the absence of added cobalamins in each of the mononuclear cell types studied. In this respect leukocyte enzyme resembles the methyltransferases of other animal tissues and bacteria (3, 11) . Since methylcobalamin is a direct participant in the bacterial methyltransferase system (1, 3, 40) , it may be assumed that in the present complete system, cyanocobalamin is reduced by P8-mercaptoethanol to B,2r which by dismutation becomes Bias which is then methylated by CHa-FHi. The modest stimulation by propylcobalamin, a cobalamin analogue incapable of converting apoenzyme to holoenzyme, indicates that about 20% of the cobalamin stimulation is attributable to the nonenzymatic Peel effect. The increased cobalamin-independent activity in anaerobic conditions has similar implications. This fact, however, does not alter the differences observed in the relative activities of cell types studied. It also does not conflict with the conclusion that most of the stimulation provided by cobalamins is independent of the Peel effect.
The precise biological function of cobalamin in lymphocytes remains a subject for speculation. As noted earlier, this enzyme may generate methionine for protein synthesis or for diverse methyl donor functions or it may provide the FHi that gives rise to cofactors needed in the synthesis of thymidylate, purine ribonucleotides, or other compounds. There is circumstantial evidence that all these roles might be operative in lymphocytes. In these cells synthesis of proteins, e.g., lymphokines (reviewed in reference 44) or immunoglobulins (45), would require a methionine source and possibly a higher methyltransferase level than in granulocytes, where these proteins are not synthesized. In addition lymphocytes display a high proliferative capacity when antigenetically stimulated.
In a number of instances, increased methyltransferase activity can be correlated with accelerated cell division, e.g., in certain phases of lymphoblastic leukemia or during the log phase of growth in phytohemagglutininstimulated lymphocytes (43) . Methyltransferase activity has been found to increase in parallel with certain enzymes known to participate in cell division (e.g., DNA polymerase and thymidine kinase) (43) . Moreover, methyltransferase activity is higher in bone marrow (the locus of active cell division) than in peripheral blood (12) . The present data also show that measurable methyltransferase activity is found in blasts of leukemic myeloid and myelomonocytic lines. Presumably, these cells, too, have a high proliferative potential. It is of interest that all of the cells shown here to contain substantial methyltransferase activity are mononuclear in type.
Investigators of leukocyte metabolism have long been aware that granulocytes are richer in glycolytic and many hydrolytic enzymes than normal and leukemic lymphocytes (46, 47) . But recent work has shown that in certain respects the enzymatic endowment of lymphocytes is superior to that of granulocytes. For example, normal blood lymphocytes have three to four times the nuclear and cytoplasmic DNA polymerase of granulocytes (48) . Also, serine hydroxymethylase is higher in CLL cells than in normal and non-CLL leukocytes (49). The relatively high methyltransferase level in normal and CLL lymphocytes must be added to this list, which presumably reflects the lymphocyte's proliferative potential. It should be noted, however, that this potential (as measured by phytohemagglutinin stimulation) is lower in CLL lymphocytes than in normal ones (50) .
Any observed metabolic difference between a normal cell and its neoplastic analogue, especially qne in which the neoplastic cell has higher activity than the normal, suggests a possible target for chemotherapeutic attack. Recently, consideration has been given to methionine depletion by means of methioninase as a possible model for cancer therapy (51, 52) . The fact that methionine depletion in the presence of adequate folate and cobalamin levels increases methyltransferase activity (7, 42, 53) may be a barrier to the success of such an approach. Moreover, the low methyltransferase activity of mature granulocytes might make them unduly sensitive to the toxic effects of such therapy. It is difficult to interpret the significance of the apparent inhibitor of E. coli methyltransferase in granulocytes until the material is purified and characterized. The present data do not establish the nature of the inhibitory effect which could operate by several mechanisms, among them, (a) inhibition of a labile form of E. coli enzyme; (b) inhibition of the conversion of apoenzyme to holoenzyme; (c) direct inhibition of holoenzyme activity; and (d) destruction or competition with methyltetrahydrofolate. It is of interest that granulocytes appear to contain inhibitor and little enzyme activity, while mononuclear cells contain substantial enzyme activity and little inhibitor (Fig. 2) . Elimination of inhibitory activity by incubation with a trypsin inhibitor suggests that one or more proteolytic enzymes of later myeloid cells may be part of the inhibitory effect. The possibility also arises that certain, possibly protein-bound, cobalamin derivatives inhibitory to methyltransferase might be present (54, 55) , especially in view of the high levels of cobalamin (56),' and cobalamin-binding proteins (38, 39) in myeloid cells. The biochemical mechanism of inhibition and insight into whether or not the apparent inhibitor of methyltransferase in myeloid cells has physiologic significance and indeed whether it has a role in suppressing the activity of endogenous enzymes will be subjects for further research. 
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